DJIA 17,051.73 -48.45 -0.28%
NASDAQ 4,424.70 -7.44 -0.17%
S&P 500 1,973.63 -4.59 -0.23%
market minute promo

Solazyme (NASDAQ: SZYM)

company name or ticker

Morgan Stanley Sees More Reasons to be Positive on Solazyme

Why Solazyme Rose After Its 2013 Year-End Results

Solazyme's CEO Management Discusses Q4 2013 Results - Earnings Call Transcript

Solazyme Inc. Discusses Q4 2013 Results (Webcast)

Attention, Solazyme Investors: Don't Forget About Amyris

Synthetic biology pioneer Amyris discussed its full-year 2013 results after market close. Here's what investors need to know about 2013 and what you can expect from operations in 2014.

Gevo: Misconceptions Create A Cheap Stock

How Solazyme, Inc. and Amyris, Inc. Bring Stability to a Risky World

Droughts and concerns of deforestation have ripped streaks of volatility through numerous raw materials that go into everyday products. Solazyme and Amyris are about to change that.

Why Solazyme's Pathway For Growth Is Beginning To Clear Up

Big Companies Are Buying Into Biofuels

Big oil and chemical companies have financial resources and established infrastructure that is, at this point, unavailable to smaller biofuel companies. In the world of biofuels, maybe size does matter.

Solazyme, Inc. and Amyris, Inc. Will Make Sluggish Economic Growth a Distant Memory

The stock market holds its breath with every monthly economic report, but it seems to be ignoring a section of the economy that accounted for 7% of all GDP growth in 2011 and 2012. What is it, and how are Solazyme and Amyris driving it higher?
See More Articles...